ALI HEALTH (00241) announced its full-year results for the period ending March 31, 2026. Total revenue reached approximately 342.55 billion yuan, representing a year-on-year increase of 12.0%. Net profit amounted to about 19.363 billion yuan, up 35.2% compared to the previous year. The adjusted net profit was 23.262 billion yuan, marking a 19.3% increase, while the adjusted net profit margin improved from 6.4% to 6.8%. The company proposed a final dividend of 5.95 cents per share and a special dividend of 13.52 cents per ordinary share.

Revenue from the pharmaceutical self-operated business was 296.65 billion yuan, a 13.6% year-on-year increase. This growth is primarily attributed to the continuous expansion of the self-operated B2C retail product categories and SKUs, as well as enhanced user experience through improved information security measures and more professional consulting services.

During the reporting period, ALI HEALTH actively developed a "launch platform for new and specialty drugs," focusing on disease areas such as diabetes, hair loss treatment, insomnia, and rhinitis. The company accelerated the launch of new drugs while improving the accessibility of innovative medicines.

As of March 31, 2026, the Taotian Medical and Health Products Service Platform operated by the group maintained stable growth, with the annualized number of active consumers (those who made at least one purchase of medical and health products on the Taobao platform, including Tmall Health, over the past 12 months) continuing to rise.

By March 31, 2026, both the number of online primary merchants and transacting merchants served by the Tmall Health platform experienced rapid growth. The number of transacting merchants increased by 26% year-on-year to 47,500, while the number of transacting SKUs grew by over 25.8% to 27.5 million.

As of March 31, 2026, the group's effective GMV (Gross Merchandise Volume) from online self-operated stores showed healthy growth. The annual number of active users and self-operated members continued to increase, with the ARPU (Average Revenue Per User) for self-operated members rising by over 14% year-on-year. Self-operated SKUs expanded by 79% to 2.2 million.

Concurrently, the group consistently enhanced the user experience for chronic disease management. During the FY26 fiscal year, the cumulative number of chronic disease payment users increased by 23% year-on-year, and the average DOT (Duration of Therapy) per user continued to grow year-on-year.

Throughout the reporting period, the group further integrated and optimized its pharmaceutical logistics network layout, continuously expanding the combination of general medicine warehouse networks and cold chain warehouse networks. Cold chain warehouses were extended to cities including Guangzhou, Hangzhou, Tianjin, Kunshan, Zhengzhou, and Chengdu, completing a new round of iterative layout.

In the medical and health services sector, by the end of the reporting period, the total number of licensed physicians, pharmacists, and nutritionists contracted to provide online health consultation services for the group increased by 12.4% year-on-year to nearly 270,000 (including Xiaolu Traditional Chinese Medicine).